Related Experiment Video

Updated: Jun 13, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Cardiac troponin I in Doberman Pinschers with cardiomyopathy

G Wess1, J Simak, M Mahling

  • 1Clinic of Small Animal Medicine, Statistical Consulting Unit, LMU University, Munich, Germany. gwess@lmu.de

Journal of Veterinary Internal Medicine
|April 24, 2010
PubMed

Insights

Cardiac troponin I (cTnI) can detect dilated cardiomyopathy (DCM) in Doberman Pinschers, even in clinically normal dogs. This cardiac biomarker aids in early diagnosis of heart disease in this breed.

Area of Science:

  • Veterinary Cardiology
  • Biomarker Research
  • Canine Health

Background:

  • Cardiac troponin I (cTnI) is a known indicator of cardiac myocyte damage.
  • Its diagnostic utility across various stages of dilated cardiomyopathy (DCM) in Doberman Pinschers remains under investigation.

Purpose of the Study:

  • To assess the diagnostic value of cTnI in identifying different stages of DCM in Doberman Pinschers.
  • To determine the efficacy of cTnI as an early detection marker for heart disease in this breed.

Main Methods:

  • A longitudinal study involving 336 Doberman Pinschers and 653 cTnI measurements.
  • Disease staging utilized 24-hour ambulatory ECG (Holter) and echocardiography.
  • Dogs were categorized into control, VPC, ECHO, VPC plus ECHO, clinical, and incipient DCM groups.

Main Results:

  • cTnI levels were significantly higher in all DCM groups compared to controls (P<.001).
  • An elevated cTnI cutoff (>0.22 ng/mL) demonstrated 79.5% sensitivity and 84.4% specificity for detecting cardiomyopathy.
  • Higher cTnI values were observed even in dogs with only ventricular premature contractions (VPCs) or incipient disease.

Conclusions:

  • Cardiac troponin I (cTnI) measurement is a valuable diagnostic tool for detecting DCM in Doberman Pinschers.
  • cTnI can identify cardiomyopathy in dogs that appear clinically normal on routine examination.
  • This biomarker aids in the early detection and management of heart disease in Dobermans.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...